QHRD106

QHRD106 is a polyethyleneglycol (PEG)-modified, long-acting tissue kallikrein preparation developed as an investigational drug for the treatment of ischemic stroke. It functions by increasing cerebral blood flow and alleviating brain injury after stroke, primarily through activation of the bradykinin receptor B2 (B2R), rather than the bradykinin receptor B1 (B1R). Mechanistically, QHRD106 reduces high-mobility group box 1 (HMGB1)-induced apoptosis and inflammation following ischemic stroke, decreases acetylated HMGB1 levels, and inhibits its translocation and release. Clinical studies have shown that QHRD106 has a slow absorption profile with prolonged pharmacodynamic effects compared to urinary kallindinogenase. It demonstrated significant improvements in cerebral blood flow in healthy volunteers with a favorable safety profile and no severe adverse events reported[1][3][4].

Other names

QH106QH-106QH 106